

11/02/01  
JC931 U.S. PTO

Page 1 of 3

12-05-01  
DIVISIONAL-CONTINUATION APPLICATION TRANSMITTAL FORM  
Customer Number: 000959  
UNDER RULE 1.53(b) (former Rule 1.60)

DOCKET NUMBER GNN-004ADV	ANTICIPATED CLASSIFICATION OF THIS APPLICATION: CLASS: 530		PRIOR APPLICATION SERIAL NUMBER: 09/644,934	PRIOR APPLICATION FILING DATE: AUGUST 23, 2000
	SUBCLASS: 350		EXAMINER: J. H. ROARK	ART UNIT: 1644

COMMISSIONER FOR PATENTS  
BOX PATENT APPLICATION  
WASHINGTON, DC 20231

10/002775  
11/02/01  
JC931 U.S. PTO

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: November 2, 2001

Mailing Label Number: EL 833315865 US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Nelson F. Barros  
Name of Person Mailing Paper

*Nelson Barros*  
Signature of Person Mailing Paper

Dear Sir:

This is a request for filing a  continuation  divisional application under 37 CFR 1.53(b), of pending prior application serial no. 09/644,934 filed on August 23, 2000, of Gordon Freeman, Vassiliki Boussiotis, Tatyana Chernova, and Nelly Malenkovich entitled Novel B7-4 Molecules & Uses Therefor.

1.  Enclosed is a copy of the latest inventor signed application, including the oath or declaration as originally filed.

The copy of the enclosed papers is as follows:

105 page(s) of specification  
 3 page(s) of claims  
 1 page(s) of abstract  
 13 sheet(s) of drawing  
 7 page(s) of declaration and power of attorney.

I hereby verify that the attached papers are a true copy of the prior complete application serial no. 09/644,934 as originally filed on August 23, 2000.

2.  Applicant claims small entity status. See 37 CFR 1.2.

3.  The filing fee is calculated below:

	NUMBER OF CLAIMS FILED	MINUS	**	20	=	NUMBER EXTRA
TOTAL	5				=	0
INDEP.	1	MINUS	***	3	=	0

MULTIPLE DEPENDENT CLAIMS

SMALL ENTITY	
RATE	FEES
x 9 =	\$0.00
x 42 =	\$0.00
+140 =	\$0.00
BASIC FEE	\$0.00
TOTAL	

OTHER THAN A SMALL ENTITY	
OR	
RATE	FEES
x 18 =	\$0.00
x 84 =	\$0.00
+ 280 =	\$0.00
BASIC FEE	\$740.00
OR	
TOTAL	\$740.00

4.  The Commissioner is hereby authorized to charge any additional fee which may be required in connection with this communication, or credit any overpayment, to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.

5.  A check in the amount of \$740.00 is enclosed for payment of the filing fee.

6.  Cancel in this application original claims 1-11, 17-24 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

7.  A preliminary amendment is enclosed. (No claims are added.)

8.  Amend the specification by inserting before the first line the sentences:

9.  Please abandon said prior application as of the filing date accorded this application. A duplicate copy of this transmittal is enclosed for filing in the prior application file. (May be used if signed by person authorized by §1.138 and before payment of base issue fee.)

10.  New informal drawings are enclosed.

11.  Priority of application serial no. \_\_\_\_\_ filed on \_\_\_\_\_ in \_\_\_\_\_ is claimed under 35 U.S.C. §119.
 

- The certified copy has been filed in prior application serial no. \_\_\_\_\_ filed on \_\_\_\_\_.
- The certified copy will follow.

12.  The prior application is assigned of record to Dana Farber Cancer Institute, Inc.

13.  A \_\_\_\_\_ month extension of time has been submitted in the parent application Serial No. in order to establish copendency with the present application.

14.  Also enclosed is/are: paper copy of Sequence Listing and a computer readable form of the Sequence Listing (diskette) statement under 37 CFR 1.821

15.  The power of attorney in the prior application is to Lahive & Cockfield, LLP.
 

- a.  The power appears in the original papers in the prior application and is enclosed.
- b.  Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c.  A new power has been executed and is attached.

16.  Address all future communications (May only be completed by applicant, or attorney or agent of record) to Amy E. Mandragouras at Customer Number: 000959 whose address is:

Lahive & Cockfield, LLP  
28 State Street  
Boston, Massachusetts 02109


17.  Any requests for extensions of time necessary in a parent application for establishing copendency between this application and a parent application are hereby requested and the Commissioner is authorized to charge any fee associated with such an extension to Deposit Account No. 12-0080.

2025 RELEASE UNDER E.O. 14176

18.  Pursuant to 37 CFR 1.821(e), the computer readable form of the sequence listing for this new application is to be identical with the computer readable form of application serial no. 10/432,700. Please use the computer readable form of application serial no. 10/432,700 in lieu of filing a duplicate computer readable form in this application. Pursuant to 37 CFR 1.821(f), the content of the paper copy of the sequence listing for this new application and the computer readable form of application serial no. 10/432,700 are the same.

November 2, 2001  
Date

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, Massachusetts 02109  
Tel. (617) 227-7400



Megan E. Williams, Esq.

Reg. No. 43,270

inventor(s)  filed under §1.34(a)  
 assignee of complete interest  
 attorney or agent of record

2025 RELEASE UNDER E.O. 14176